Abstract
BACKGROUND: The global incidence of hyperlipidemia has been increasing on an annual basis, concomitant with improvements in living standards and dietary changes. Hyperlipidemia is closely associated with the development of numerous diseases, and in clinical cases, drug-induced cholestasis may lead to elevated serum cholesterol and triglyceride levels, a phenomenon known as secondary hyperlipidemia. Hyperlipidemia is recognized as a significant risk factor for the development of cardiovascular disease. Therefore, effective monitoring and control of lipid levels is crucial in the management of patients diagnosed with drug-induced cholestatic liver disease. CASE SUMMARY: We present a special case of refractory hyperlipidemia associated with cholestatic liver disease in a 49-year-old woman. CONCLUSION: In the treatment of clinical cases of drug-induced cholestatic liver disease and hyperlipidemia, it is essential for medical professionals to consider the patient's overall condition, formulate an individualized treatment plan, and closely monitor the patient's biochemical indices and clinical symptoms to ensure treatment efficacy and prognosis.